Curocell
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood c… Read more
Curocell (372320) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.405x
Based on the latest financial reports, Curocell (372320) has a cash flow conversion efficiency ratio of -0.405x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.05 Billion) by net assets (₩19.88 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Curocell - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Curocell's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Curocell Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curocell ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Microvast Holdings Inc
NASDAQ:MVST
|
0.042x |
|
AUBAY TECHNOL. INH.EO 05
F:BAQ
|
N/A |
|
Sysgration Ltd
TWO:5309
|
-0.013x |
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
N/A |
|
Amarin Corporation PLC
NASDAQ:AMRN
|
0.033x |
|
Shenzhen Longood Intelligent Electric Co Ltd Class A
SHE:300543
|
0.030x |
|
Canandaigua National Corporation
PINK:CNND
|
0.099x |
|
China Catalyst Holding Co. Ltd. A
SHG:688267
|
0.047x |
Annual Cash Flow Conversion Efficiency for Curocell (2021–2024)
The table below shows the annual cash flow conversion efficiency of Curocell from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩29.45 Billion | ₩-28.42 Billion | -0.965x | -125.73% |
| 2023-12-31 | ₩59.10 Billion | ₩-25.26 Billion | -0.427x | -241.38% |
| 2022-12-31 | ₩-47.60 Billion | ₩-14.39 Billion | 0.302x | -67.93% |
| 2021-12-31 | ₩-12.24 Billion | ₩-11.54 Billion | 0.943x | -- |